WASHINGTON (MedPage Today) — Incentives in the Senate healthcare bill meant to encourage healthy lifestyles unfairly target the poor, elderly, overweight, and disabled, and could be exploited by insurance companies for financial gain, advocacy groups claim.
No Comments »
Filed under: General Health News
Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the 725th event (patient death) has been reached in its pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy.
No Comments »
Filed under: Pharmacy News
ACCESS PHARMACEUTICALS, INC., today announced that it has completed enrollment and evaluation of the last additional cohort of patients in the ongoing clinical study of ProLindac as a monotherapy in ovarian cancer patients who have received at least two prior platinum based treatment regimens.
No Comments »
Filed under: Pharmacy News
Tolerx, Inc., today announced the completion of patient enrollment in its Phase 3 clinical study DEFEND-1, which is evaluating the safety and efficacy of otelixizumab, a targeted T cell immunomodulator, in patients with new-onset autoimmune type 1 diabetes.
No Comments »
Filed under: Pharmacy News
University Hospitals Case Medical Center is one of 12 sites conducting the first Phase 2 clinical trial of a gene therapy for Alzheimer’s disease (AD). The study uses a viral-based gene transfer system called CERE-110, which is designed to deliver nerve growth factor (NGF) into the brain.
No Comments »
Filed under: Pharmacy News
Elixir Pharmaceuticals, Inc. announced today that its partner, Siena Biotech S.p.A., has commenced Phase 1 clinical testing of Elixir’s potent, first-in-class SIRT1 (sirtuin-1) inhibitor for the treatment of Huntington’s Disease.
No Comments »
Filed under: Pharmacy News
NexBio, Inc. announced today the initiation of a double blind placebo controlled multi-center trial in the U.S. and Mexico of DAS181 (Fludase®) for the treatment of laboratory confirmed influenza infection.
No Comments »
Filed under: Pharmacy News
Pfizer Inc. (Pfizer) and Debiopharm Group™ (Debiopharm) announced today that they have entered into a co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma.
No Comments »
Filed under: Pharmacy News
VIVUS, Inc. today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development of Qnexa for the treatment of obesity and submitted a New Drug Application (NDA) to the FDA for that indication.
No Comments »
Filed under: Pharmacy News
The University of Maryland Biotechnology Institute (UMBI) has announced the exclusive licensing of a fully human antibody technology platform to Prolias, a biotechnology company working to discover and develop novel therapeutic proteins and antibodies for treatment of disease. The announcement was made by Dr. Theodore J. Roumel, UMBI’s VP for Research, Innovation and Commercialization…
No Comments »
Filed under: Pharmacy News
